ANNX earnings analysis
What we found in ANNX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Annexon’s Q2 2026 diluted EPS loss improved year over year to $0.28 from $0.34, but the company remains unprofitable, reporting a $55.3 million quarterly net loss and no product revenue from sales. Liquidity strengthened through $209.2 million of cash, cash equivalents and short-term investments plus a $200.0 million credit facility, but the facility introduces variable-rate debt and asset-security risks. The principal outlook remains milestone-driven rather than financial: FORWARD data and a targeted tanruprubart BLA submission are expected in 2026, while the FDA has warned that additional GBS patient data may be required.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Year-over-year EPS loss improved
- Diluted EPS was a loss of $0.28, improving from a $0.34 loss in Q2 2025, although it was below the $0.24 consensus estimate.
- Liquidity supports runway into 2028
- Cash and cash equivalents plus short-term investments totaled approximately $209.2 million at June 30, 2026, which management expects to fund planned operating expenses into 2028.
- New credit facility expands liquidity
- The July 30, 2026 Loan Agreement provides term loans of up to $200.0 million, including an initial $50.0 million funded at closing.
- Clinical-stage programs remain active
- Management reported net losses of approximately $55.3 million for the three months and $99.5 million for the six months ended June 30, 2026, versus annual losses of $206.7 million in 2025 and $138.2 million in 2024.
- Regulatory package advancing
- The company expects initial PK, PD, biomarker and functional data from the FORWARD study in the second half of 2026 to supplement the tanruprubart GBS regulatory package.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Debt adds interest and covenant risk
- The newly disclosed Loan Agreement carries interest at the greater of 1-month CME Term SOFR plus 4.6% or 7.60%, is secured by substantially all assets, and includes up to $200.0 million of term loans. Variable-rate debt, covenants and potential acceleration could constrain financial flexibility.
- FDA may require additional GBS data
- The company states that the FDA has indicated its tanruprubart generalizability package may not support BLA approval absent additional patient data, despite targeting a BLA submission in 2026.
- Persistent losses may require financing
- Annexon had an accumulated deficit of approximately $1.0 billion as of June 30, 2026 and expects to continue incurring losses; it also states that additional financing may be needed sooner than planned despite a runway into 2028.
- Equity issuance and warrant dilution
- The company sold $32.2 million under its new $150 million at-the-market program as of the filing date, creating potential dilution, while 29,765,799 shares were issuable upon exercise of pre-funded warrants as of June 30, 2026.
- Reporting status change raises costs
- Because the market value of common stock held by non-affiliates exceeded $700 million as of June 30, 2026, the company will lose smaller-reporting-company status beginning with the Form 10-Q for the quarter ending March 31, 2027, increasing compliance costs.
- ARCHER II execution and funding risk
- The global ARCHER II Phase 3 program for vonaprument may be substantially more expensive and longer than planned, and the company states it may need additional capital to complete the program.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.28
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects initial FORWARD study data in the second half of 2026, intends to submit a tanruprubart BLA in 2026, and expects existing capital resources to fund planned operating expenses into 2028.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Annexon, Inc. did not report any revenue for Q4 2026, continuing its trend of operating losses with a net loss of $44.1 million, an improvement from $54.4 million in Q4 2025. Management remains focused on pivotal…
- 10-K · March 30, 2026
- Annexon is a clinical-stage biopharma advancing a C1q-targeting platform with two late-stage registrational programs: tanruprubart for Guillain-Barré Syndrome (MAA filed with EMA in January 2026) and vonaprument for…
- 10-Q · November 10, 2025
- Annexon reported a Q3 2025 GAAP net loss of $54,922,000 (EPS -$0.37) versus a net loss of $34,824,000 (EPS -$0.25) in Q3 2024, driven by higher R&D spending of $49,700,000 (up from $30,105,000). The company holds cash…
- 10-Q · August 14, 2025
- Annexon reported a wider GAAP net loss for Q2 2025 as operating expenses rose sharply driven by R&D; GAAP net loss was $(49,156) (thousands) and net loss per share was $(0.34) versus $(0.23) in Q2 2024. Cash and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ANNX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever